S1609 three-year analysis of the daliah trial - a randomized controlled phase iii clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms
T.A. Knudsen,D. Lund Hansen,L. Frans Ocias,O. Weis Bjerrum,M. Brabrand,C. Ellervik,D. el Fassi,M. Frederiksen,L. Kjær,T. Kielsgaard,T. A. Kruse,H. T. Mourits-Andersen,P. Møller,U. M. Overgaard,D. Andersen Patel,M. Tang Severinsen,V. Skov,A. Lindholm Sørensen,J. Stentoft,J. Starklint,K. de Stricker,M. Thomassen,T. Stauffer Larsen,H. Hasselbalch
